Our Pricing

Can Mounjaro Cause Heart Palpitations? Understanding Tirzepatide's Cardiovascular Safety Profile

Published: 10 September 2026

Many patients ask: can Mounjaro cause heart palpitations when starting this weight loss treatment? While heart palpitations are not listed as a common side effect in clinical trials, some individuals may experience increased heart rate or palpitations, particularly during the initial adjustment period or due to indirect factors such as dehydration, electrolyte imbalance, or rapid weight loss[1]. Understanding the cardiovascular safety profile of tirzepatide helps patients make informed decisions and recognise when to seek medical guidance.

Can Mounjaro Cause Heart Palpitations: What Clinical Trials Show

The question of whether can Mounjaro cause heart palpitations has been extensively studied in the SURPASS clinical trial programme, which enrolled over 10,000 participants[1]. These large-scale studies did not identify heart palpitations as a common adverse event, with cardiovascular safety data showing favourable outcomes. In fact, the SELECT cardiovascular outcomes trial demonstrated that tirzepatide reduced major adverse cardiovascular events by 15% compared to placebo in adults with established cardiovascular disease[2].

However, individual responses vary, and some patients report sensations of heart racing or palpitations, particularly during the first few weeks of treatment. These experiences are often related to the body's metabolic adjustments rather than direct cardiac toxicity. The SURPASS-4 trial, which specifically monitored cardiovascular safety in patients with type 2 diabetes and increased cardiovascular risk, found no increased incidence of arrhythmias or palpitations compared to insulin glargine[1].

Why Can Mounjaro Cause Heart Palpitations in Some Patients: Common Mechanisms

Understanding why can Mounjaro cause heart palpitations in certain individuals requires examining several physiological mechanisms. Tirzepatide works by activating GIP and GLP-1 receptors, which slow gastric emptying and reduce appetite[3]. This mechanism can lead to reduced fluid intake in some patients, potentially causing dehydration—a well-known trigger for palpitations and increased heart rate.

Additionally, the rapid weight loss achieved with Mounjaro (average 15-21% body weight reduction in clinical trials) can trigger metabolic shifts that affect electrolyte balance[1]. Potassium, magnesium, and sodium levels may fluctuate, particularly in the first 8-12 weeks of treatment, and electrolyte imbalances are established causes of cardiac rhythm disturbances. Patients who experience significant nausea or vomiting—reported in approximately 20-30% of users—face higher risk of dehydration and electrolyte depletion[3].

Indirect Cardiovascular Effects of Weight Loss

The cardiovascular system undergoes significant adaptation during substantial weight loss. As body mass decreases, cardiac workload changes, blood pressure typically improves, and autonomic nervous system regulation may temporarily shift. These positive long-term changes can occasionally manifest as transient palpitations during the adjustment period, particularly in patients losing weight rapidly or those with pre-existing cardiovascular conditions.

Can Mounjaro Cause Heart Palpitations: Identifying Risk Factors

Certain patient populations may be more susceptible when asking can Mounjaro cause heart palpitations in their specific case. Individuals with pre-existing cardiac conditions, including arrhythmias, coronary artery disease, or heart failure, should discuss cardiovascular monitoring with their prescriber before starting tirzepatide[2]. A thorough medical history and baseline ECG may be recommended for high-risk patients.

Other risk factors include concurrent use of medications that affect heart rhythm, such as certain antidepressants, decongestants, or stimulants. Patients with thyroid disorders, anxiety conditions, or those consuming high levels of caffeine may also experience heightened sensitivity to metabolic changes. Age over 65, particularly in combination with multiple cardiovascular risk factors, warrants closer monitoring during the initial treatment phase[4].

Medication Interactions and Cardiac Effects

Mounjaro can slow gastric emptying, which may affect the absorption and peak concentrations of other medications, including cardiac drugs. Patients taking beta-blockers, calcium channel blockers, or antiarrhythmic medications should inform their prescriber, as dosage adjustments may be necessary. The interaction between tirzepatide and medications that lower blood pressure or heart rate requires careful titration to avoid excessive cardiovascular effects[3].

When Can Mounjaro Cause Heart Palpitations That Require Medical Attention

While mild, transient palpitations may occur as the body adjusts to Mounjaro, certain symptoms warrant immediate medical evaluation. Patients should seek urgent care if palpitations are accompanied by chest pain, severe shortness of breath, dizziness leading to near-fainting, or palpitations lasting more than a few minutes[4]. These symptoms may indicate more serious cardiac events that require assessment regardless of Mounjaro use.

Persistent palpitations occurring daily, particularly if they worsen over time or interfere with normal activities, should be discussed with your prescriber. A 24-hour Holter monitor or event recorder may be recommended to characterise the rhythm disturbance and determine whether it relates to Mounjaro therapy or represents an underlying cardiac condition. In most cases, simple interventions such as improved hydration, electrolyte supplementation, or dose adjustment can resolve the issue[2].

Can Mounjaro Cause Heart Palpitations: Prevention and Management Strategies

Patients concerned about whether can Mounjaro cause heart palpitations can take proactive steps to minimise risk. Maintaining adequate hydration is paramount—aim for at least 2 litres of water daily, increasing intake during hot weather or exercise. Monitoring for signs of dehydration, such as dark urine, dizziness, or dry mouth, helps catch issues early before they affect cardiac rhythm[3].

Electrolyte balance can be supported through dietary choices rich in potassium (bananas, spinach, avocados) and magnesium (nuts, whole grains, leafy greens). Some patients benefit from electrolyte replacement drinks, particularly if experiencing nausea or reduced food intake. Limiting caffeine and alcohol, both of which can trigger palpitations independently, may reduce symptom frequency. Gradual dose escalation, following the prescribed titration schedule, allows the body to adapt to tirzepatide's effects and minimises sudden metabolic shifts[1].

Monitoring and Follow-Up Protocols

Regular follow-up with your prescriber allows for early detection and management of cardiovascular concerns. At Cured Pharmacy, our UK-registered clinical team provides ongoing support throughout your Mounjaro journey, with superintendent pharmacist Tarun Kumar (GPhC 2233073) overseeing all prescribing decisions. Patients should report any new or persistent palpitations during routine check-ins, typically scheduled at 4-week intervals during the initial treatment phase. Blood pressure and heart rate monitoring at home can provide valuable data for clinical assessment.

Can Mounjaro Cause Heart Palpitations: Long-Term Cardiovascular Outcomes

When evaluating whether can Mounjaro cause heart palpitations as a long-term concern, the evidence is reassuring. The SELECT trial, which followed patients for an average of 3 years, demonstrated that tirzepatide significantly reduced cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 15% compared to placebo[2]. This cardiovascular benefit far outweighs the risk of transient palpitations in most patients.

Long-term weight loss achieved with Mounjaro contributes to improved cardiovascular health through multiple mechanisms: reduced blood pressure, improved lipid profiles, decreased inflammation, and enhanced insulin sensitivity[1]. These metabolic improvements translate to lower long-term risk of atrial fibrillation, heart failure, and coronary artery disease. For patients who experience palpitations during the initial treatment phase, the cardiovascular benefits of sustained weight loss typically justify continued therapy under medical supervision.

Mounjaro is available at Cured Pharmacy from £124.99, with all prescriptions requiring clinical assessment by a UK-registered prescriber. Our transparent pricing and free online consultation (completed in under 3 minutes) ensure you receive expert guidance on cardiovascular safety throughout your weight loss journey. New patients receive £20 off their first order with code Weightlossnew, making evidence-based weight loss treatment accessible and affordable[4].

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 10 September 2026]
2. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. [accessed 10 September 2026]
3. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 10 September 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. [accessed 10 September 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 10 September 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 10 September 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 10 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.